Molecular Diagnostics for Lung Cancer

  • Ashok KumarEmail author
  • Ashwani Tandon


Lung cancers are characterized by numerous genomic aberrations and some of them are sufficient to induce cell growth and impair the differentiation. These mutations are termed as driver mutations and include base substitutions, insertions, deletions, translocation and amplifications. With the advent of recent technologies these abnormalities can be detected precisely. There is paradigm shift in the diagnosis and current management of lung cancers from morphology to molecular analysis. Molecular characterization of lung cancers has allowed the identification of subsets of non-small lung cancers and provided new treatment targets which ultimately lead to more personalized or stratified targeted therapies. In this chapter, we discuss classification, common patho-genetic abnormalities and various methods for molecular diagnosis of lung cancers. We have also summarized emerging technologies for molecular diagnostics and the recommendations and expert consensus opinion according to current guidelines.


Lung cancer NSCLC FISH qRT-PCR Next generation sequencing 


  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. Epub 2014/09/16.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80. Epub 2008/09/26.Google Scholar
  3. 3.
    Inamura K. Lung cancer: understanding its molecular pathology and the 2015 WHO classification. Front Oncol. 2017;7:193. Epub 2017/09/13.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7(9). Epub 2017/09/08.Google Scholar
  5. 5.
    Bhatt M, Kant S, Bhaskar R. Pulmonary tuberculosis as differential diagnosis of lung cancer. South Asian J Cancer. 2012;1(1):36–42. Epub 2012/07/01.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57. Epub 2009/08/21.PubMedGoogle Scholar
  7. 7.
    Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–60. Epub 2015/08/21.PubMedGoogle Scholar
  8. 8.
    Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–81. Epub 2007/02/24.PubMedGoogle Scholar
  9. 9.
    Cooper WA, Lam DC, O’Toole SA, Minna JD. Molecular biology of lung cancer. J Thorac Dis. 2013;5(Suppl 5):S479–90. Epub 2013/10/29.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458(7239):719–24. Epub 2009/04/11.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(Suppl 4):S3–8. Epub 2001/10/13.PubMedGoogle Scholar
  12. 12.
    Fujimoto J, Wistuba II. Current concepts on the molecular pathology of non-small cell lung carcinoma. Semin Diagn Pathol. 2014;31(4):306–13. Epub 2014/09/23.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46. Epub 2012/01/31.PubMedGoogle Scholar
  14. 14.
    Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39. Epub 2004/05/01.PubMedGoogle Scholar
  15. 15.
    Wang S, Song Y, Yan F, Liu D. Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. Front Med. 2016;10(4):383–8. Epub 2016/10/23.PubMedGoogle Scholar
  16. 16.
    Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, Khotskaya YB, et al. ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud. 2017;3(1):a001115. Epub 2017/01/05.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Hofman P. ALK in non-small cell lung cancer (NSCLC) pathobiology, epidemiology, detection from tumor tissue and algorithm diagnosis in a daily practice. Cancers. 2017;9(8). Epub 2017/08/15.Google Scholar
  18. 18.
    Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res. 2013;19(15):4040–5. Epub 2013/05/31.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Rossi G, Jocolle G, Conti A, Tiseo M, Zito Marino F, Donati G, et al. Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives. Lung Cancer (Auckl). 2017;8:45–55. Epub 2017/07/26.Google Scholar
  20. 20.
    Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer. 2014;14(3):173–86. Epub 2014/02/25.PubMedGoogle Scholar
  21. 21.
    Takeuchi S, Murayama T, Yoshimura K, Kawakami T, Takahara S, Imai Y, et al. Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol. J Med Invest. 2017;64(3.4):317–20. Epub 2017/09/29.PubMedGoogle Scholar
  22. 22.
    Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4(12):915–25. Epub 2003/12/20.PubMedGoogle Scholar
  23. 23.
    Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(10):1667–74. Epub 2009/03/04.Google Scholar
  24. 24.
    Zhang Y, Wang W, Wang Y, Xu Y, Tian Y, Huang M, et al. Response to crizotinib observed in lung adenocarcinoma with MET copy number gain but without a high-level MET/CEP7 ratio, MET overexpression, or exon 14 splicing mutations. J Thorac Oncol. 2016;11(5):e59–62. Epub 2016/01/03.PubMedGoogle Scholar
  25. 25.
    Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–7. Epub 2013/03/09.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta. 2005;1756(2):81–2. Epub 2005/11/05.PubMedGoogle Scholar
  27. 27.
    Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(31):4769–77. Epub 2010/10/06.Google Scholar
  28. 28.
    Kempf E, Rousseau B, Besse B, Paz-Ares L. KRAS oncogene in lung cancer: focus on molecularly driven clinical trials. Eur Respir Rev. 2016;25(139):71–6. Epub 2016/03/02.PubMedGoogle Scholar
  29. 29.
    Xu CX, Jin H, Shin JY, Kim JE, Cho MH. Roles of protein kinase B/Akt in lung cancer. Front Biosci (Elite Ed). 2010;2:1472–84. Epub 2010/06/03.Google Scholar
  30. 30.
    Scheffler M, Bos M, Gardizi M, Konig K, Michels S, Fassunke J, et al. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies. Oncotarget. 2015;6(2):1315–26. Epub 2014/12/05.PubMedGoogle Scholar
  31. 31.
    Shim HS, Choi YL, Kim L, Chang S, Kim WS, Roh MS, et al. Molecular testing of lung cancers. J Pathol Transl Med. 2017;51(3):242–54. Epub 2017/04/22.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Hiley CT, Le Quesne J, Santis G, Sharpe R, de Castro DG, Middleton G, et al. Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet. 2016;388(10048):1002–11. Epub 2016/09/07.PubMedGoogle Scholar
  33. 33.
    O’Brien CP, Taylor SE, O’Leary JJ, Finn SP. Molecular testing in oncology: problems, pitfalls and progress. Lung Cancer. 2014;83(3):309–15. Epub 2014/01/30.PubMedGoogle Scholar
  34. 34.
    Conklin CM, Craddock KJ, Have C, Laskin J, Couture C, Ionescu DN. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 2013;8(1):45–51. Epub 2012/12/01.PubMedGoogle Scholar
  35. 35.
    Boyle TA, Masago K, Ellison KE, Yatabe Y, Hirsch FR. ROS1 immunohistochemistry among major genotypes of non-small-cell lung cancer. Clin Lung Cancer. 2015;16(2):106–11. Epub 2014/12/04.PubMedGoogle Scholar
  36. 36.
    Khoo C, Rogers TM, Fellowes A, Bell A, Fox S. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. Transl Lung Cancer Res. 2015;4(2):126–41. Epub 2015/04/15.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Roma C, Esposito C, Rachiglio AM, Pasquale R, Iannaccone A, Chicchinelli N, et al. Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology. Biomed Res Int. 2013;2013:385087. Epub 2013/12/24.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Weber B, Meldgaard P, Hager H, Wu L, Wei W, Tsai J, et al. Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer. 2014;14:294. Epub 2014/04/30.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Lang AH, Drexel H, Geller-Rhomberg S, Stark N, Winder T, Geiger K, et al. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J Mol Diagn. 2011;13(1):23–8. Epub 2011/01/14.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Sheikine Y, Rangachari D, McDonald DC, Huberman MS, Folch ES, VanderLaan PA, et al. EGFR testing in advanced non-small-cell lung cancer, a mini-review. Clin Lung Cancer. 2016;17(6):483–92. Epub 2016/10/23.PubMedGoogle Scholar
  41. 41.
    Storm N, Darnhofer-Patel B, van den Boom D, Rodi CP. MALDI-TOF mass spectrometry-based SNP genotyping. Methods Mol Biol. 2003;212:241–62. Epub 2002/12/21.PubMedGoogle Scholar
  42. 42.
    Serrati S, De Summa S, Pilato B, Petriella D, Lacalamita R, Tommasi S, et al. Next-generation sequencing: advances and applications in cancer diagnosis. OncoTargets Ther. 2016;9:7355–65. Epub 2016/12/17.Google Scholar
  43. 43.
    In Vitro Diagnostics [database on the Internet]. US Food and Drug Administration. 2017 [cited 26 Oct 2017].
  44. 44.
    Ansari J, Yun JW, Kompelli AR, Moufarrej YE, Alexander JS, Herrera GA, et al. The liquid biopsy in lung cancer. Genes Cancer. 2016;7(11–12):355–67. Epub 2017/02/14.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Zhang Z, Ramnath N, Nagrath S. Current status of CTCs as liquid biopsy in lung cancer and future directions. Front Oncol. 2015;5:209. Epub 2015/10/21.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta. 2001;313(1–2):139–42. Epub 2001/11/06.PubMedGoogle Scholar
  47. 47.
    Mouliere F, Robert B, Arnau Peyrotte E, Del Rio M, Ychou M, Molina F, et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One. 2011;6(9):e23418. Epub 2011/09/13.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Alegre E, Fusco JP, Restituto P, Salas-Benito D, Rodriguez-Ruiz ME, Andueza MP, et al. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. Tumour Biol. 2016;37(10):13687–94. Epub 2016/07/31.PubMedGoogle Scholar
  49. 49.
    Mohrmann L, Huang H, Hong DS, Tsimberidou AM, Fu S, Piha-Paul S, et al. Liquid biopsies using plasma exosomal nucleic acids and plasma cell-free DNA compared with clinical outcomes of patients with advanced cancers. Clin Cancer Res. 2018;24(1):181–8. Epub 2017/10/21.PubMedGoogle Scholar
  50. 50.
    Zhu YJ, Zhang HB, Liu YH, Zhu YZ, Chen J, Li Y, et al. Association of mutant EGFR L858R and exon 19 concentration in circulating cell-free DNA using droplet digital PCR with response to EGFR-TKIs in NSCLC. Oncol Lett. 2017;14(2):2573–9. Epub 2017/08/10.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Sozzi G, Roz L, Conte D, Mariani L, Andriani F, Lo Vullo S, et al. Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am J Respir Crit Care Med. 2009;179(1):69–74. Epub 2008/09/13.PubMedGoogle Scholar
  52. 52.
    Li X, Liu Y, Shi W, Xu H, Hu H, Dong Z, et al. Droplet digital PCR improved the EGFR mutation diagnosis with pleural fluid samples in non-small-cell lung cancer patients. Clin Chim Acta. 2017;471:177–84. Epub 2017/06/13.PubMedGoogle Scholar
  53. 53.
    Sorensen BS, Wu L, Wei W, Tsai J, Weber B, Nexo E, et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer. 2014;120(24):3896–901. Epub 2014/08/12.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489(7417):519–25. Epub 2012/09/11.Google Scholar
  55. 55.
    Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol. 2013;8(7):823–59. Epub 2013/04/05.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Molecular Testing guideline for selection of lung cancer patients – revision 2016 draft recommendations. IASLC; 2016 [cited 2017 30 Nov 2017].

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of BiochemistryAll India Institute of Medical SciencesBhopalIndia
  2. 2.Department of Pathology and Laboratory MedicineAll India Institute of Medical SciencesBhopalIndia

Personalised recommendations